Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 23,600 shares of the firm’s stock in a transaction that occurred on Thursday, July 27th. The stock was bought at an average cost of $6.34 per share, for a total transaction of $149,624.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $19,457,149.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, July 26th, Phillip Md Et Al Frost bought 36,200 shares of Opko Health stock. The stock was bought at an average cost of $6.39 per share, for a total transaction of $231,318.00.
  • On Tuesday, July 25th, Phillip Md Et Al Frost bought 39,800 shares of Opko Health stock. The stock was bought at an average cost of $6.41 per share, for a total transaction of $255,118.00.
  • On Monday, July 24th, Phillip Md Et Al Frost bought 45,000 shares of Opko Health stock. The stock was bought at an average cost of $6.42 per share, for a total transaction of $288,900.00.
  • On Thursday, July 20th, Phillip Md Et Al Frost bought 5,400 shares of Opko Health stock. The stock was bought at an average cost of $6.46 per share, for a total transaction of $34,884.00.
  • On Monday, July 17th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The stock was bought at an average cost of $6.04 per share, for a total transaction of $10,872.00.
  • On Friday, July 14th, Phillip Md Et Al Frost bought 12,600 shares of Opko Health stock. The stock was bought at an average cost of $6.16 per share, for a total transaction of $77,616.00.
  • On Wednesday, July 12th, Phillip Md Et Al Frost bought 3,600 shares of Opko Health stock. The stock was bought at an average cost of $6.12 per share, for a total transaction of $22,032.00.
  • On Monday, July 10th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The stock was bought at an average cost of $6.19 per share, for a total transaction of $309,500.00.
  • On Thursday, July 6th, Phillip Md Et Al Frost bought 25,000 shares of Opko Health stock. The stock was bought at an average cost of $6.29 per share, for a total transaction of $157,250.00.
  • On Monday, July 3rd, Phillip Md Et Al Frost bought 60,800 shares of Opko Health stock. The stock was bought at an average cost of $6.44 per share, for a total transaction of $391,552.00.

Opko Health, Inc. (NASDAQ OPK) traded up 0.237% during mid-day trading on Friday, hitting $6.335. 468,968 shares of the stock were exchanged. Opko Health, Inc. has a 52 week low of $5.99 and a 52 week high of $12.15. The company has a 50 day moving average price of $6.48 and a 200 day moving average price of $7.49. The stock’s market cap is $3.54 billion.

Opko Health (NASDAQ:OPK) last issued its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by $0.02. The firm had revenue of $296.10 million during the quarter, compared to analyst estimates of $313.36 million. Opko Health had a negative net margin of 3.60% and a negative return on equity of 2.13%. The business’s revenue for the quarter was up 1.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.02) earnings per share. Analysts expect that Opko Health, Inc. will post ($0.20) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Phillip Md Et Al Frost Purchases 23,600 Shares of Opko Health, Inc. (NASDAQ:OPK) Stock” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/28/phillip-md-et-al-frost-purchases-23600-shares-of-opko-health-inc-nasdaqopk-stock.html.

Hedge funds have recently made changes to their positions in the stock. Financial Architects Inc boosted its stake in shares of Opko Health by 45.0% in the second quarter. Financial Architects Inc now owns 15,460 shares of the biotechnology company’s stock worth $102,000 after buying an additional 4,800 shares during the period. AQR Capital Management LLC bought a new stake in shares of Opko Health during the fourth quarter worth $105,000. Timber Hill LLC bought a new stake in shares of Opko Health during the first quarter worth $114,000. Comerica Bank bought a new stake in shares of Opko Health during the fourth quarter worth $117,000. Finally, World Asset Management Inc boosted its stake in shares of Opko Health by 23.6% in the first quarter. World Asset Management Inc now owns 15,176 shares of the biotechnology company’s stock worth $121,000 after buying an additional 2,900 shares during the period. Hedge funds and other institutional investors own 23.64% of the company’s stock.

Several research analysts recently commented on OPK shares. BidaskClub upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a report on Monday. Ladenburg Thalmann Financial Services restated a “buy” rating and issued a $19.50 price target on shares of Opko Health in a report on Friday, June 16th. Zacks Investment Research upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Barrington Research raised their price target on shares of Opko Health to $11.00 and gave the company an “outperform” rating in a report on Tuesday, July 18th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $8.00 price target on shares of Opko Health in a report on Monday, June 12th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $14.72.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.